“Paragon’s release represents years of technology development and validation work to move molecular profiling of cancer tissues out of the analog approaches that persist today, and into the digital world.” said Dr. Jarret Glasscock, Chief Executive Officer of Cofactor Genomics.

“The cancer immune cycle is complex, necessitating sensitive and robust RNA-based technologies to inform treatment decisions. Technologies like Cofactor Paragon will facilitate current drug development and fuel the future of precision medicine”

Cofactor’s Paragon assay reports on the most impactful immune modulatory molecules demonstrated to have implications in drug discovery, biomarker development, and immunotherapy efficacy monitoring. 

Cofactor Genomics introduces Paragon, an RNA-based immune profiling assay which enables a unique look into an oncology patient’s immune profile – far beyond traditional “hot” or “cold” classification.

Clinical archives and samples such as FFPE, FNAs, CNBs, and LCM solid tumors have previously been difficult to characterize.  Paragon accommodates these valuable and degraded materials with very low inputs and provides extensive immune characterization beyond current technologies – including differentiating cells such as M1 and M2 macrophages and Tregs – with high confidence. Find new biomarkers or improve patient selection as you transition from translational to clinical research applications.

Submit your samples to Cofactor and we’ll deliver a fully-analyzed data set highlighting immune escape genes and immune cell profiles, in one easy-to-interpret report. Don’t settle for qualitative, generic characterization from disparate assays such as IHC, flow cytometry, or expression arrays.  Gain novel immune insights quickly and confidently.

Cofactor’s Paragon Assay is for Research Use Only and should not be used as a diagnostic assay.